Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Growth 2023-2029

Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Growth 2023-2029

Irritable bowel syndrome (IBS) is a common disorder that affects the large intestine. Signs and symptoms include cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both. IBS is a chronic condition that need to manage long term.
IBS that causes increased diarrhea is often called IBS-D. Diarrhea predominant irritable bowel syndrome (IBS-D) is a subtype of IBS in which a person experiences frequent episodes of diarrhea with accompanying abdominal pain. Like IBS, IBS-D is a functional gastrointestinal disorder (FGD) in that there is no visible disease, inflammation, or injury to account for its symptoms. It is estimated that approximately a third of people who have IBS experience the disorder with diarrhea as the predominant bowel habit.
In this report, we study the drugs for diarrhea predominant irritable bowel syndrome (IBS-D).
LPI (LP Information)' newest research report, the “Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Forecast” looks at past sales and reviews total world Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales for 2023 through 2029. With Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs industry.
This Insight Report provides a comprehensive analysis of the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs and breaks down the forecast by type, by sales channel, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs.
The global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size is projected to grow from US$ 1357.9 million in 2022 to US$ 2837 million in 2029; it is expected to grow at a CAGR of 2837 from 2023 to 2029.
North America is the largest consumption place of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, followed by Europe. The two account for more than 80% of the consumer market in together. The most used IBS-D drug is XIFAXAN, accounting for more than 60% of the market share, followed by Viberzi and Lotronex. IBS-D drugs are widely sold through hospital pharmacies and retail pharmacies.
This report presents a comprehensive overview, market shares, and growth opportunities of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market by product type, sales channel, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
XIFAXAN
Viberzi
Lotronex
Other
Segmentation by sales channel
Hospitals Pharmacy
Retail Pharmacy
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bausch Health
Allergan
Sebela Pharmaceuticals
Astellas Pharmaceuticals
Amneal Pharms
Pharscin Pharma

Key Questions Addressed in this Report
What is the 10-year outlook for the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market?
What factors are driving Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market opportunities vary by end market size?
How does Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs break out type, sales channel?
What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.